Leveraging Next-Gen Sequencing, Bioinformatics & -Omics Technologies to Identify & Validate Novel Targets & Regulatory Elements in the Dark Genome
Thank you to our speakers, sponsors, and delegates who joined us in 2025 for the summit! If you are interested in our future events, please get in touch at info@hansonwade.com
The Inaugural Dark Genome Target Discovery & Development Summit
The Dawn of the Dark Genome Has Arrived...
With HAYA Therapeutics closing $65M series A financing to continue pioneering LncRNA targeted therapeutics across multiple disease areas, and UbiVac releasing promising clinical data from their vaccine-induced TCR against a dark genome-derived antigen, it is evident that the dark genome’s long-hidden potential has final started coming to light.
The inaugural Dark Genome Target Discovery & Development Summit was crafted as the first industry-focused forum dedicated to deciphering the mysteries of non-coding DNA and RNA to harness its potential across oncology, neuroscience, aging, heart disease and beyond!
In 2025, world-class experts at ROME Therapeutics, HAYA Therapeutics, Mnemo Therapeutics, HERVolution, CAMP4 Therapeutics, Enara Bio, Immatics and more, came together to gain the tangible insights and strategies across discovery, genomics, proteomics, data science, AI, bioinformatics and computational biology to enlighten a new paradigm for drug discovery.
Our 2025 World-Class Speaker Faculty Included
